[
    {
        "headline": "Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News",
        "text": "Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use its additive product."
    },
    {
        "headline": "With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?",
        "text": "Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line."
    },
    {
        "headline": "S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'",
        "text": "Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags."
    },
    {
        "headline": "HistoSonics secures first insurance coverage for histotripsy system",
        "text": "Michigan is the first US state to offer reimbursement for Histonics’ FDA-approved Edison histotripsy system."
    },
    {
        "headline": "Trump expected to sign order to slash US drug prices",
        "text": "President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this act. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers",
        "text": "The \"Magnificent Seven,\" made up of Nvidia (NVDA), Alphabet (GOOG, GOOGL), Tesla (TSLA), Microsoft (MSFT), Amazon (AMZN), Meta (META), and Apple (AAPL), are rallying after the US and China agreed to lower tariff rates for a 90-day period. Airline stocks, like American Airlines (AAL), Delta (DAL), and United Airlines (UAL), are also gaining on the trade deal. Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck (MRK), are moving to the downside after US President Trump said he will cut drug prices by over 50%. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "US-China trade truce, April CPI, drug prices: 3 Things",
        "text": "US stock futures (ES=F, NQ=F, YM=F) are surging Monday morning after US and China officials agreed to significant cuts to each country's respective tariff rates in a 90-day cool-off period. April's Consumer Price Index (CPI) is due out tomorrow, reporting month-over-month trends in US inflation rates. President Trump vows to cut prescription drug prices by as much as 80%. In turn, pharmaceutical stocks are seeing across the board pullbacks in pre-market trading. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices",
        "text": "Pfizer (PFE), AstraZeneca (AZN), Johnson & Johnson (JNJ), and other drug company shares fell in Mond"
    },
    {
        "headline": "J&J reports new data from Phase III trial of icotrokinra for plaque psoriasis",
        "text": "The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin."
    },
    {
        "headline": "Is Johnson & Johnson (JNJ) the Best Income Stock to Invest in Now?",
        "text": "We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive […]"
    },
    {
        "headline": "Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback",
        "text": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment for psoriasis, while facing legal challenges from a jury awarding a $3 million verdict linked to baby powder use. These developments coincided with a 3.77% rise in the company's stock over the past month. This price movement reflects broader market trends, as the Dow Jones was relatively flat amid ongoing U.S.-China tariff discussions. Johnson & Johnson's positive..."
    },
    {
        "headline": "J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study",
        "text": "The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals. J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 2028. BTIG analyst Julian Harrison expects icotrokinra to \"complement rather than disrupt\" market leaders, including J&J's Tremfya and AbbVie's Skyrizi."
    },
    {
        "headline": "Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis",
        "text": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites."
    },
    {
        "headline": "Is Johnson & Johnson (JNJ) the Best Medical Device Stock to Buy Now?",
        "text": "We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs […]"
    },
    {
        "headline": "Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
        "text": "Zymeworks Inc (ZYME) reports a significant revenue increase and strong cash position, while navigating rising expenses and strategic uncertainties."
    },
    {
        "headline": "A Look at Pharma ETFs After Strong Q1 Earnings",
        "text": "Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both."
    },
    {
        "headline": "Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Net Sales Outlook",
        "text": "Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates."
    },
    {
        "headline": "Johnson & Johnson expands efforts to champion the nursing workforce globally",
        "text": "NEW BRUNSWICK, N.J., May 08, 2025--Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every step of their career journey and strengthen health systems worldwide. The expansion aims to help address the global shortfall of nu"
    },
    {
        "headline": "FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight",
        "text": "The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for American consumers and patients. This change builds upon the agency’s Office of Inspection and Investigations’ Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and"
    },
    {
        "headline": "Is Johnson & Johnson (JNJ) the Best Dow Stock?",
        "text": "We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength of […]"
    },
    {
        "headline": "Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News",
        "text": "Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use its additive product."
    },
    {
        "headline": "With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?",
        "text": "Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line."
    },
    {
        "headline": "S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'",
        "text": "Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags."
    },
    {
        "headline": "HistoSonics secures first insurance coverage for histotripsy system",
        "text": "Michigan is the first US state to offer reimbursement for Histonics’ FDA-approved Edison histotripsy system."
    },
    {
        "headline": "Trump expected to sign order to slash US drug prices",
        "text": "President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this act. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers",
        "text": "The \"Magnificent Seven,\" made up of Nvidia (NVDA), Alphabet (GOOG, GOOGL), Tesla (TSLA), Microsoft (MSFT), Amazon (AMZN), Meta (META), and Apple (AAPL), are rallying after the US and China agreed to lower tariff rates for a 90-day period. Airline stocks, like American Airlines (AAL), Delta (DAL), and United Airlines (UAL), are also gaining on the trade deal. Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck (MRK), are moving to the downside after US President Trump said he will cut drug prices by over 50%. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "US-China trade truce, April CPI, drug prices: 3 Things",
        "text": "US stock futures (ES=F, NQ=F, YM=F) are surging Monday morning after US and China officials agreed to significant cuts to each country's respective tariff rates in a 90-day cool-off period. April's Consumer Price Index (CPI) is due out tomorrow, reporting month-over-month trends in US inflation rates. President Trump vows to cut prescription drug prices by as much as 80%. In turn, pharmaceutical stocks are seeing across the board pullbacks in pre-market trading. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices",
        "text": "Pfizer (PFE), AstraZeneca (AZN), Johnson & Johnson (JNJ), and other drug company shares fell in Mond"
    },
    {
        "headline": "J&J reports new data from Phase III trial of icotrokinra for plaque psoriasis",
        "text": "The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin."
    },
    {
        "headline": "Is Johnson & Johnson (JNJ) the Best Income Stock to Invest in Now?",
        "text": "We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive […]"
    },
    {
        "headline": "Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback",
        "text": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment for psoriasis, while facing legal challenges from a jury awarding a $3 million verdict linked to baby powder use. These developments coincided with a 3.77% rise in the company's stock over the past month. This price movement reflects broader market trends, as the Dow Jones was relatively flat amid ongoing U.S.-China tariff discussions. Johnson & Johnson's positive..."
    },
    {
        "headline": "J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study",
        "text": "The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals. J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 2028. BTIG analyst Julian Harrison expects icotrokinra to \"complement rather than disrupt\" market leaders, including J&J's Tremfya and AbbVie's Skyrizi."
    },
    {
        "headline": "Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis",
        "text": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites."
    },
    {
        "headline": "Is Johnson & Johnson (JNJ) the Best Medical Device Stock to Buy Now?",
        "text": "We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs […]"
    },
    {
        "headline": "Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
        "text": "Zymeworks Inc (ZYME) reports a significant revenue increase and strong cash position, while navigating rising expenses and strategic uncertainties."
    }
]